Access cutting-edge hidradenitis suppurativa treatment through this clinical trial at a research site in Tampa. Study-provided care at no cost to qualified participants.
Access hidradenitis suppurativa specialists in Tampa at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hidradenitis suppurativa treatment provided free
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this hidradenitis suppurativa clinical trial in Tampa, FL
If you're searching for hidradenitis suppurativa treatment options in Tampa, FL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Tampa research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hidradenitis suppurativa specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.